【提要】  非酒精性脂肪性肝病(NAFLD)是与IR、肥胖和高脂血症密切相关的临床综合征。IR是T2DM和NAFLD共同的发病机制之一。一些降糖药物除降糖作用外还有控制体重、调节血脂和改善IR等特点，但有的本身具有药物性肝损害（DILI）。降糖药物是否对NAFLD产生影响尚无定论，本文就各类降糖药物和NAFLD的相关研究进展作一综述。

【关键词】  非酒精性脂肪性肝病；糖尿病，2型；胰岛素抵抗 

       Research progress of hypoglycemic agents and non-alcoholic fatty liver disease

【Summary】 Non-alcoholic fatty liver disease (NAFLD) is a clinical syndrome closely associated with IR, obesity and hyperlipidemia. IR plays a role in both NAFLD and T2DM pathogenesis. Some hypoglycemic agents can control body weight; regulate blood lipid and lower insulin resistance beside their anti-hyperglycemic effects. However, some of them can cause drug-induced liver injury (DILI). Whether hypoglycemic agents have any effect on NAFLD was unknown. Here we summarize the research progress in a variety of hypoglycemic agents and NAFLD for reference.

【Key words】  Non-alcoholic fatty liver disease (NAFLD)；Diabetes mellitus, type 2；Insulin resistance (IR)